Metformin, SGLT2 Inhibitors Exhibit Significantly Lower Dementia Risk
Metformin displayed lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had highest risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.